Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OPRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOptimizeRx appoints Mary Varghese Presti to Board, expands to seven directors
Filed April 9, 2026 · Period ending April 3, 2026 · ~1 min read
Key Changes
-
medium
Mary Varghese Presti appointed as independent director effective April 3, 2026, serving until the 2026 annual meeting. Board expanded from six to seven members to accommodate the appointment.
Item 5.02 verify on EDGAR → -
medium
Varghese Presti assigned to Audit Committee, which oversees financial reporting and internal controls. This strengthens the committee's oversight capabilities.
Item 5.02 verify on EDGAR → -
low
New director will receive standard compensation: $55,000 annual cash retainers ($45,000 base plus $10,000 for Audit Committee service) and approximately $175,000 in annual equity grants.
Item 5.02 verify on EDGAR →
Summary
OptimizeRx expanded its Board of Directors from six to seven members with the appointment of Mary Varghese Presti as an independent director, effective April 3, 2026. The appointment came upon recommendation from the Board's Nominating & Governance Committee and represents a continuation of the company's Board refresh efforts. Varghese Presti will serve until the 2026 annual stockholder meeting and has been assigned to the Audit Committee.
For retail investors, this is a routine governance matter that modestly strengthens board oversight, particularly in financial reporting through the Audit Committee assignment. The compensation package follows the company's existing director pay structure with no unusual terms. Watch for the company's proxy statement ahead of the 2026 annual meeting, which will provide Varghese Presti's full background and qualifications, helping investors assess whether her expertise aligns with OptimizeRx's strategic priorities in the digital health technology space.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
In connection with Ms. Varghese Presti’s appointment to the Board, the Board expanded the size of the Board to seven members from its current six members. The Board also appointed Ms. Varghese Presti to serve as a member of the Audit Committee.
The Board expanded from six to seven members to accommodate the new director. Ms. Varghese Presti was also appointed to the Audit Committee, which oversees financial reporting and internal controls.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 8, 2026, the Company issued a press release announcing the appointment of Ms. Varghese Presti to its Board.
OptimizeRx disclosed the appointment of Ms. Varghese Presti to its Board of Directors. The company issued a press release on April 8, 2026 to announce this board change. No additional details about Ms. Presti's background or the circumstances of the appointment are provided in the 8-K body itself.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify